Wall Street Zen Upgrades Compugen (NASDAQ:CGEN) to “Buy”

Compugen (NASDAQ:CGEN) was upgraded by stock analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a report released on Saturday.

Other equities analysts also recently issued reports about the company. Weiss Ratings restated a “sell (d-)” rating on shares of Compugen in a report on Wednesday, January 21st. HC Wainwright began coverage on shares of Compugen in a research note on Wednesday, January 7th. They issued a “buy” rating and a $4.00 price target on the stock. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Compugen has a consensus rating of “Hold” and an average target price of $4.00.

Compugen Stock Up 1.5%

Shares of CGEN opened at $2.08 on Friday. The stock has a market cap of $185.62 million, a P/E ratio of 5.62 and a beta of 2.90. The business’s 50 day moving average price is $1.84 and its 200-day moving average price is $1.67. Compugen has a 52 week low of $1.13 and a 52 week high of $2.38.

Compugen (NASDAQ:CGEN) last posted its quarterly earnings data on Monday, March 2nd. The biotechnology company reported $0.60 earnings per share for the quarter, beating analysts’ consensus estimates of $0.05 by $0.55. The company had revenue of $67.33 million during the quarter, compared to analyst estimates of $14.30 million. Compugen had a return on equity of 55.68% and a net margin of 48.57%. On average, equities analysts anticipate that Compugen will post -0.03 EPS for the current year.

Institutional Trading of Compugen

Several large investors have recently added to or reduced their stakes in CGEN. Bank Hapoalim BM purchased a new stake in Compugen during the fourth quarter valued at approximately $37,000. Security National Bank of Sioux City Iowa IA purchased a new position in shares of Compugen during the 4th quarter worth $38,000. Franklin Resources Inc. purchased a new position in shares of Compugen during the 2nd quarter worth $56,000. Osaic Holdings Inc. grew its position in shares of Compugen by 346.0% during the 2nd quarter. Osaic Holdings Inc. now owns 43,885 shares of the biotechnology company’s stock valued at $78,000 after acquiring an additional 34,045 shares during the period. Finally, WINTON GROUP Ltd purchased a new stake in shares of Compugen in the 4th quarter worth $84,000. 12.22% of the stock is currently owned by institutional investors.

Compugen Company Profile

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.